Generali Group的子公司在Biogen公司投资了410万美元,该公司是一家生物技术公司,具有“坚持”评级。 Generali Group's subsidiary invested $4.1 million in Biogen Inc., a biotech firm with a "Hold" rating.

Generali Group的子公司在Biogen公司投资410万美元,购买了27 060股股票。 Generali Group's subsidiary invested $4.1 million in Biogen Inc., buying 27,060 shares. 生物基因的市场上限为220.1亿美元,它报告的EPS为3.44美元,超过估计值。 Biogen, with a market cap of $22.01 billion, reported an EPS of $3.44, exceeding estimates. 以神经疾病为重点的生物技术公司已经看到各种机构调整了它们的利害关系。 The biotech firm, focusing on neurological diseases, has seen various institutions adjust their stakes. 分析员预测该年Biogen的EPS为15.83,评级为“延迟”,价格目标为213.33美元。 Analysts predict Biogen's EPS at 15.83 for the year, with a "Hold" rating and a price target of $213.33.